Health disparity in use of novel agents for first-line therapy in Black and White patients with chronic lymphocytic leukemia in the Department of Veterans Affairs

BACKGROUND: Novel agents (NAs) (ibrutinib, idelalisib, and venetoclax) were first introduced in 2013 as therapeutic options to treat chronic lymphocytic leukemia (CLL). OBJECTIVES: To determine if the uptake of NAs for first-line treatment was similar in Black and White patients with CLL treated in...

Descripción completa

Detalles Bibliográficos
Autores principales: Lucero, Kana Tai, Obodozie-Ofoegbu, Obiageri O, Nooruddin, Zohra, Ryan, Kellie, Castillo, Alyssa, Moore, Amanda M, Jones, Xavier, Frei, Christopher R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387978/
https://www.ncbi.nlm.nih.gov/pubmed/36989449
http://dx.doi.org/10.18553/jmcp.2023.29.4.420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387978/
https://www.ncbi.nlm.nih.gov/pubmed/36989449
http://dx.doi.org/10.18553/jmcp.2023.29.4.420

Ejemplares similares